论文部分内容阅读
目的:探索治疗类风湿关节炎有效且经济的方案。方法:选择2009年5月至12月份105例在我院住院的类风湿关节炎患者,对符合纳入标准的入选病例,根据治疗方案随机分为依那西普治疗A组35例、依那西普治疗B组35例和对照组35例。所有患者都在治疗前及治疗开始后不同时间点(2、4、6、8、12、16、24周)进行关节功能相关指标检测。结果:治疗结束后,三组患者的各项关节功能指标均较治疗前明显改善(P<0.05);其中,依那西普治疗A、B组均优于对照组(P<0.05)。在治疗后第2、4周,依那昔普治疗A组达到ACR50改善标准的患者比例明显高于B组(P<0.05)。结论:小剂量依那西普联合甲氨蝶呤作为治疗类风湿关节炎的可选方案之一,有效且费用较低。
Objective: To explore effective and economical treatment of rheumatoid arthritis. Methods: A total of 105 patients with rheumatoid arthritis hospitalized in our hospital from May to December in 2009 were enrolled. According to the treatment plan, 35 patients were randomly divided into group A, General treatment group B 35 cases and control group 35 cases. All patients were detected before treatment and at different time points after treatment (2,4,6,8,12,16,24 weeks) for the detection of joint function-related indicators. Results: After the treatment, the joint function indexes of the three groups were significantly improved (P <0.05), while those of Etanercept group A and B were better than the control group (P <0.05). In the first and second week after treatment, the proportion of patients in group A receiving ACR50 improvement was significantly higher than that in group B (P <0.05). Conclusions: Etanercept in combination with methotrexate is an effective and cost effective alternative to rheumatoid arthritis.